---
title: "BIOLQ.US (BIOLQ.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BIOLQ.US/news.md"
symbol: "BIOLQ.US"
name: "BIOLQ.US"
parent: "https://longbridge.com/en/quote/BIOLQ.US.md"
datetime: "2026-05-22T00:46:01.471Z"
locales:
  - [en](https://longbridge.com/en/quote/BIOLQ.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BIOLQ.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BIOLQ.US/news.md)
---

# BIOLQ.US (BIOLQ.US) — Related News

### [15:05 ETBioLab Holdings Earns Great Place to Work® Certification](https://longbridge.com/en/news/281067196.md)
*2026-03-30T19:07:17.000Z*
> BioLab Holdings has earned the Great Place to Work® certification, reflecting its commitment to a positive workplace cul

### [Sonendo Expands Portfolio and Pursues Damages Against Biolase](https://longbridge.com/en/news/215792311.md)
*2024-10-02T11:00:52.000Z*
> Sonendo, Inc. (SONX) is set to acquire dental laser system assets from Biolase in a bankruptcy court-supervised sale, ac

### [BIOLASE Voluntarily Initiates Chapter 11 Proceedings | BIOL Stock News](https://longbridge.com/en/news/215745113.md)
*2024-10-01T20:05:00.000Z*
> BIOLASE, Inc. has voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court for Delaware, aiming to cont

### [12 Health Care Stocks Moving In Thursday's After-Market Session](https://longbridge.com/en/news/201764148.md)
*2024-04-11T20:31:16.000Z*
> Health care stocks showed mixed performance in Thursday's after-market session. Gainers included Ontrak, Ocuphire Pharma

### [Ascendiant Capital Maintains Buy on Biolase, Lowers Price Target to $4](https://longbridge.com/en/news/201060751.md)
*2024-04-01T09:40:28.000Z*
> Ascendiant Capital analyst Edward Woo maintains Biolase (NASDAQ:BIOL) with a Buy and lowers the price target from $15 to

### [Benchmark Maintains Speculative Buy on Biolase, Lowers Price Target to $0.4](https://longbridge.com/en/news/200489025.md)
*2024-03-22T17:42:01.000Z*
> Benchmark analyst Bruce Jackson maintains Biolase (NASDAQ:BIOL) with a Speculative Buy and lowers the price target from